RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Freeline Therapeutics Holdings Stock

Freeline Therapeutics Holdings Market capitalization 2024

Freeline Therapeutics Holdings Market capitalization

25.6 M USD

Ticker

FRLN

ISIN

US35655L1070

WKN

A2QADU

In 2024, Freeline Therapeutics Holdings's market cap stood at 25.6 M USD, a -4.9% increase from the 26.91 M USD market cap in the previous year.

The Freeline Therapeutics Holdings Market capitalization history

YEARMarket Capitalization (undefined USD)
202253.2
2021296.76
2020600.27
2019-
2018-

Freeline Therapeutics Holdings Aktienanalyse

What does Freeline Therapeutics Holdings do?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Freeline Therapeutics Holdings's Market Capitalization

Freeline Therapeutics Holdings's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Freeline Therapeutics Holdings's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Freeline Therapeutics Holdings's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Freeline Therapeutics Holdings’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Freeline Therapeutics Holdings stock

What is the current Freeline Therapeutics Holdings market capitalization?

The current market capitalization of Freeline Therapeutics Holdings is 25.6 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Freeline Therapeutics Holdings.

How has the market capitalization of Freeline Therapeutics Holdings developed in recent years?

The market capitalization of Freeline Therapeutics Holdings has increased/decreased by -4.9% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Freeline Therapeutics Holdings?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Freeline Therapeutics Holdings?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Freeline Therapeutics Holdings have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Freeline Therapeutics Holdings pay?

Over the past 12 months, Freeline Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Freeline Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Freeline Therapeutics Holdings?

The current dividend yield of Freeline Therapeutics Holdings is .

When does Freeline Therapeutics Holdings pay dividends?

Freeline Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Freeline Therapeutics Holdings?

Freeline Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Freeline Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Freeline Therapeutics Holdings located?

Freeline Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Freeline Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Freeline Therapeutics Holdings from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Freeline Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Freeline Therapeutics Holdings in the year 2023?

In the year 2023, Freeline Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Freeline Therapeutics Holdings pay out the dividend?

The dividends of Freeline Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Freeline Therapeutics Holdings

Our stock analysis for Freeline Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Freeline Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.